Atlas One · Host Biology · Scale 07 — System

Myeloproliferative Neoplasms

Myeloproliferative neoplasms (PV, ET, MF) are driven by JAK2 V617F in >95% of PV and ~50-60% of ET/MF; CALR and MPL mutations account for remaining cases. Ruxolitinib (JAK1/2 inhibitor) is standard for myelofibrosis and PV; alloSCT is curative for high-risk MF.

Also known as: myeloproliferative neoplasms, MPN, polycythemia vera, PV, essential thrombocythemia, ET, myelofibrosis, MF, primary myelofibrosis, JAK2 V617F MPN, Philadelphia-negative MPN

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
myeloproliferative-neoplasms

Myeloproliferative Neoplasms

Myeloproliferative neoplasms (PV, ET, MF) are driven by JAK2 V617F in >95% of PV and ~50-60% of ET/MF; CALR and MPL mutations account for remaining cases. Ruxolitinib (JAK1/2 inhibitor) is standard for myelofibrosis and PV; alloSCT is curative for high-risk MF.

Entry Metadata

FieldValue
IDmyeloproliferative-neoplasms
NameMyeloproliferative Neoplasms
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toJak1 2 connects-toStat3 connects-toErythropoietin connects-toTgf Beta connects-toPolycythemia Vera connects-toJak2 connects-toBone Marrow connects-toCmml connects-toMyelofibrosis connects-toSpleen

Sources